
|Videos|January 11, 2018
Examining Response Rates in MSI-H and NTRK Fusion GI Cancers
Author(s)Luis A. Diaz, M.D.
Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.
Advertisement
Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.
Finding these biomarkers in patients with GI cancers can be particularly important, as it can help choose a treatment plan that can have a dramatic response in this group of patients.
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Updates Safety Warnings for Common Chemotherapy Drugs
2
Real-World Data with Amtagvi Show High Response Rates in Advanced Melanoma
3
FDA Removes Use Limitation for Yescarta in Primary CNS Lymphoma
4
Chemo Brain is Real: My Experience with a Clinical Study and What It Can Teach Us
5




